Abstract
could be attributed to specific donors. Results: A total of 34 patients (mean age 68.8 years, 67.6% female) received at least 1 dose of RBX2660. Nineteen patients received 1 dose and 15 patients received 2 doses. The individual donor or the order of donors made no difference in the success or failure of treatment with RBX2660. This was especially clear in the case of 1 patient who received 2 doses of the exact same product (both doses from the same donor and same batch). The first dose failed and the second was a success. The donor to patient results for the cohort receiving 2 doses is shown in Figure 2 as an example. Similar trends were observed for patients receiving a single dose. Conclusion: Based on an analysis of small numbers, it appears that the specific donor does not affect the outcomes of RBX2660 for recurrent CDI. Additional research with a larger patient cohort and comparative analysis of donor and patient microbiota communities is needed to provide more details on patientspecific factors predisposing to success or failure with this therapy. RBX2660 Outcomes by Donor
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
